Novo Nordisk brings back former CEO as chairman
Lars Rebien Sorensen returns as Novo Nordisk chairman after board shakeup. The move follows Pfizer's $10B Metsera acquisition, intensifying obesity drug competition.
Lars Rebien Sorensen returns as Novo Nordisk chairman after board shakeup. The move follows Pfizer's $10B Metsera acquisition, intensifying obesity drug competition.